Selected research
Industry Research
Multivalent Vaccines Industry Research Report 2026
Market perspective
The global Multivalent Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Multivalent Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Multivalent Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Multivalent Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Multivalent Vaccines include Bavarian Nordic (Denmark), CSL Limited (Australia), Daiichi Sankyo (Japan), Emergent BioSolutions, Inc(US), GlaxoSmithKline, plc (U.K.), MedImmune, LLC (US), Mitsubishi Tanabe Pharma Corporation (Japan), Panacea Biotec (India) and Protein Sciences Corporation (US), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Multivalent Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Multivalent Vaccines Market by Company
Bavarian Nordic (Denmark)
CSL Limited (Australia)
Daiichi Sankyo (Japan)
Emergent BioSolutions, Inc(US)
GlaxoSmithKline, plc (U.K.)
MedImmune, LLC (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Panacea Biotec (India)
Protein Sciences Corporation (US)
Serum Institute of India Pvt. Ltd. (India)
Astellas Pharma Inc. (Japan)
Pfizer, Inc(US)
Merck & Co., Inc(US)
Johnson & Johnson (US)
Sanofi Pasteur SA (France)
Multivalent Vaccines Segment by Type
Toxoid Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated and Subunit Vaccines
Recombinant Vaccines
Multivalent Vaccines Segment by Application
Pediatrics
Adults
Multivalent Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multivalent Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Multivalent Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Multivalent Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Toxoid Vaccines
- Live Attenuated Vaccines
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Recombinant Vaccines
Applications
- Pediatrics
- Adults
Companies covered
- Bavarian Nordic (Denmark)
- CSL Limited (Australia)
- Daiichi Sankyo (Japan)
- Emergent BioSolutions, Inc(US)
- GlaxoSmithKline, plc (U.K.)
- MedImmune, LLC (US)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Panacea Biotec (India)
- Protein Sciences Corporation (US)
- Serum Institute of India Pvt. Ltd. (India)
- Astellas Pharma Inc. (Japan)
- Pfizer, Inc(US)
- Merck & Co., Inc(US)
- Johnson & Johnson (US)
- Sanofi Pasteur SA (France)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Multivalent Vaccines Market Size (2021-2032)
- 2.2.2 Global Multivalent Vaccines Sales (2021-2032)
- 2.2.3 Global Multivalent Vaccines Market Average Price (2021-2032)
- 2.3 Multivalent Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Toxoid Vaccines
- 2.3.3 Live Attenuated Vaccines
- 2.3.4 Conjugate Vaccines
- 2.3.5 Inactivated and Subunit Vaccines
- 2.3.6 Recombinant Vaccines
- 2.4 Multivalent Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pediatrics
- 2.4.3 Adults
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Multivalent Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Multivalent Vaccines Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Multivalent Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Multivalent Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Multivalent Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Multivalent Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Multivalent Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Multivalent Vaccines, Established Date
- 3.9 Global Multivalent Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bavarian Nordic (Denmark)
- 4.1.1 Bavarian Nordic (Denmark) Company Information
- 4.1.2 Bavarian Nordic (Denmark) Business Overview
- 4.1.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
- 4.1.5 Bavarian Nordic (Denmark) Recent Developments
- 4.2 CSL Limited (Australia)
- 4.2.1 CSL Limited (Australia) Company Information
- 4.2.2 CSL Limited (Australia) Business Overview
- 4.2.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
- 4.2.5 CSL Limited (Australia) Recent Developments
- 4.3 Daiichi Sankyo (Japan)
- 4.3.1 Daiichi Sankyo (Japan) Company Information
- 4.3.2 Daiichi Sankyo (Japan) Business Overview
- 4.3.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
- 4.3.5 Daiichi Sankyo (Japan) Recent Developments
- 4.4 Emergent BioSolutions, Inc(US)
- 4.4.1 Emergent BioSolutions, Inc(US) Company Information
- 4.4.2 Emergent BioSolutions, Inc(US) Business Overview
- 4.4.3 Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio
- 4.4.5 Emergent BioSolutions, Inc(US) Recent Developments
- 4.5 GlaxoSmithKline, plc (U.K.)
- 4.5.1 GlaxoSmithKline, plc (U.K.) Company Information
- 4.5.2 GlaxoSmithKline, plc (U.K.) Business Overview
- 4.5.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
- 4.5.5 GlaxoSmithKline, plc (U.K.) Recent Developments
- 4.6 MedImmune, LLC (US)
- 4.6.1 MedImmune, LLC (US) Company Information
- 4.6.2 MedImmune, LLC (US) Business Overview
- 4.6.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
- 4.6.5 MedImmune, LLC (US) Recent Developments
- 4.7 Mitsubishi Tanabe Pharma Corporation (Japan)
- 4.7.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
- 4.7.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
- 4.7.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
- 4.7.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
- 4.8 Panacea Biotec (India)
- 4.8.1 Panacea Biotec (India) Company Information
- 4.8.2 Panacea Biotec (India) Business Overview
- 4.8.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
- 4.8.5 Panacea Biotec (India) Recent Developments
- 4.9 Protein Sciences Corporation (US)
- 4.9.1 Protein Sciences Corporation (US) Company Information
- 4.9.2 Protein Sciences Corporation (US) Business Overview
- 4.9.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
- 4.9.5 Protein Sciences Corporation (US) Recent Developments
- 4.10 Serum Institute of India Pvt. Ltd. (India)
- 4.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information
- 4.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
- 4.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
- 4.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
- 4.11 Astellas Pharma Inc. (Japan)
- 4.11.1 Astellas Pharma Inc. (Japan) Company Information
- 4.11.2 Astellas Pharma Inc. (Japan) Business Overview
- 4.11.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
- 4.11.5 Astellas Pharma Inc. (Japan) Recent Developments
- 4.12 Pfizer, Inc(US)
- 4.12.1 Pfizer, Inc(US) Company Information
- 4.12.2 Pfizer, Inc(US) Business Overview
- 4.12.3 Pfizer, Inc(US) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Pfizer, Inc(US) Multivalent Vaccines Product Portfolio
- 4.12.5 Pfizer, Inc(US) Recent Developments
- 4.13 Merck & Co., Inc(US)
- 4.13.1 Merck & Co., Inc(US) Company Information
- 4.13.2 Merck & Co., Inc(US) Business Overview
- 4.13.3 Merck & Co., Inc(US) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio
- 4.13.5 Merck & Co., Inc(US) Recent Developments
- 4.14 Johnson & Johnson (US)
- 4.14.1 Johnson & Johnson (US) Company Information
- 4.14.2 Johnson & Johnson (US) Business Overview
- 4.14.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
- 4.14.5 Johnson & Johnson (US) Recent Developments
- 4.15 Sanofi Pasteur SA (France)
- 4.15.1 Sanofi Pasteur SA (France) Company Information
- 4.15.2 Sanofi Pasteur SA (France) Business Overview
- 4.15.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
- 4.15.5 Sanofi Pasteur SA (France) Recent Developments
5 Global Multivalent Vaccines Market Scenario by Region
- 5.1 Global Multivalent Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Multivalent Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Multivalent Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Multivalent Vaccines Sales by Region: 2027-2032
- 5.3 Global Multivalent Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Multivalent Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Multivalent Vaccines Revenue by Region: 2027-2032
- 5.4 North America Multivalent Vaccines Market Facts & Figures by Country
- 5.4.1 North America Multivalent Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Multivalent Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Multivalent Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Multivalent Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Multivalent Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Multivalent Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Multivalent Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Multivalent Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Multivalent Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Multivalent Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Multivalent Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Multivalent Vaccines Market Facts & Figures by Country
- 5.7.1 South America Multivalent Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Multivalent Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Multivalent Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Multivalent Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Multivalent Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Multivalent Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Multivalent Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Multivalent Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Multivalent Vaccines Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Multivalent Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Multivalent Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Multivalent Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Multivalent Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Multivalent Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Multivalent Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Multivalent Vaccines Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Multivalent Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Multivalent Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Multivalent Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Multivalent Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Multivalent Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Multivalent Vaccines Value Chain Analysis
- 8.1.1 Multivalent Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Multivalent Vaccines Production Mode & Process
- 8.2 Multivalent Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Multivalent Vaccines Distributors
- 8.2.3 Multivalent Vaccines Customers
9 Global Multivalent Vaccines Analyzing Market Dynamics
- 9.1 Multivalent Vaccines Industry Trends
- 9.2 Multivalent Vaccines Industry Drivers
- 9.3 Multivalent Vaccines Industry Opportunities and Challenges
- 9.4 Multivalent Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst